Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Thursday, July 2

1 - --I I

A42
Chairs:
Venue:
Time:

Animal Models for Vaccine Development
Sam Avrett, Reinhard Kurth
Session Hall III
13.00-14.30

546 Attenuated SIV vaccines: Safety and efficacy following
heterologous challenge
Mark G. Lewis*; F. Novembre; R. Desrosiers; Y. Lu; E. Rud;
V. Hirsch; D. Birx, USA
547 Role of b-chemokines in protective immunity against
intrarectal SlVsm challenge of macaques
Rigmor Thorstensson*; R. Ahmed; C. Wilson; P. Putkonen;
Y. Wang; T. Lehner; G. Biberfeld, Sweden
548 Recombinant vaccine-induced protection against the highly
pathogenic SlVmac251 dependence on route of challenge
exposure
Geneoveffa Franchini, USA
549 Protective T-cell mediated immunity induced by a consecutive
HIV-1 DNA and avipox vaccine regimen
Stephen Kent*; A. Zhao; E.M. Dax; J.D. Chandler; H.L. Robinson;
D.B. Boyle; I.A. Ramshaw, Australia
550 Potent neutralization of primary HIV-1 isolates by antisera
induced upon immunization with a recombinant protein
expressing the native V1/V2 domain of gpl 20
Abraham Pinter*; O0. Trochev; WJ. Honnen; Z Wu; S. Reiken;
M. Lewis; S.C. Kayman, USA
551 Multi-subtype envelope-based DNA and protein immunization
strategies for broadening immune responses to HIV-1
Susan W. Barnett*; Y. Sun; H.S. Legg; T.C. VanCott;
J.R. Mascola; F.M. Sinangil, USA

11238
11239
21200
21198
21194
21196

B44 Neurological Complications of HIV
Chairs: Paola Cinque, Christina M. Marra
Venue: Session Hall IV
Time: 13.00-14.30
558 Latest developments in neuropathogenesis
To be confirmed
559 Animal models of HIV neuropathogenesis
Dominique Dormont
560 Predictive markers for HIV-associated dementia and 32191
sensory neuropathy
Elizabeth Childs*; Justin C McArthur; R.H. Lyles; E. Miller;
B.A. Cohen; B.B. Chen; J. Mellors; J.C. McArthur, USA
561 Safety and efficacy of abacavir (ABC, 1592) in AIDS dementia 32192
complex (Study CNAB 3001)
Bruce James Brew*; S.J. Brown; J. Catalan; N. Sacktor;
M. Halman; W.T Symonds; C. Romero; CNAB 3001 Study Team,
Australia
562 Progressive multifocal leukoencephalopathy (PML) 32193
treatment with cidofovir
Rustam Al-Shahi*; M. Sadler; E. Davies; M.R. Nelson;
B.G. Gazzard, UK
563 Evidence for independent development of RT inhibitor (RTI) 32284
resistance patterns in cerebrospinal fluid (CSF) compartment
Philip Cunningham*; D. Smith; C. Satchell; D.A. Cooper;
B.J. Brew, Australia
564 Stavudine stops neuro-AIDS in AZT-non-responders 32207
Gabriele Arendt*; H.-J. v. Giesen; H. Jablonowski, Germany
B45 Bridging Session: Issues in Clinical Trial Design
Chairs: Lynda Dee, Markus Flepp
Venue: Arena
Time: 13.00-14.30
565 What kinds of trials?

A43 Pre-Clinical Drug Development
Chairs: D.J. Back,T.Smart
Venue: Session Hall VII
Time: 13.00-14.30

I

552 Introduction
J. Condra
553 S-1153, a new nonnucleoside reverse transcriptase inhibitor
of HIV-1
Tamio Fujiwara*; A. Sato; M. EI-Farrash; Y. Wu3; L. Chen;
M. Hatanaka; Y. Hinuma, Japan
554 Cellular pharmacology of the antiviral agents PMPA
and PMEA in vitro and in vivo
Arnold Fridland*; B. Robbins; J. Rodman; C.C Tsai;
N. Bischofberger, USA
555 A resistance surmountable HIV protease inhibitor effective
against both wild-type and new analogs of HIV-1 protease
Yoshiaki Kiso*; M. Kishida; H. Matsumoto; S. Mizumoto;
T. Kimura, Japan
556 Abacavir (1592, ABC) prevents spread of HIV-1 in brain
tissue of SCID mice with HIV-1 encephalitis
Jenae Limoges*; D.R. McClernon; Y. Persidsky;J. Rasmussen;
E.R. Lanier; J. Reinhard; H.E. Gendelman, USA
557 Anti-HIV activity, biochemistry,and pharmacokinetics
of b-D-2',3'-didehydro-2',3'-dideoxy-5- fluorocytidine
(D-D4FC)
Raymond Schinazi*; L. Ma; J. Shi; D. Liotta; A. Faraj;
JP. Sommadossi, USA
180

41181

Ann Collier
566 The role of cohort studies
Andrew Phillips
567 Trials in developing countries
Praphan Phanuphak
568 The patients' perspective
James Kreppner

41175

41212
11233
41174
Pathway Symbol: Policy

12th World AIDS Conference Geneva